ArticleJournal of virology2000
Anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency.
Article in Journal of virology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 66 citations in OpenAlex.
- Immune reconstitution and viral stimulation are required to restore HIV-specific CD8 T cell responses following advanced infection.Journal of clinical immunology · 2004Trial
- Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.Proceedings of the National Academy of Sciences of the United States of America · 2001Trial
- T-cell activation state differentially contributes to neuropsychiatric complications in women with HIV.Brain, behavior, & immunity - health · 2022Article
- STING Ligand-Mediated Priming of Functional CD8Journal of virology · 2021Article
- CD8Frontiers in immunology · 2019Review
- Have Cells Harboring the HIV Reservoir Been Immunoedited?Frontiers in immunology · 2019Article
- CD8+ lymphocyte control of SIV infection during antiretroviral therapy.PLoS pathogens · 2018Article
- Article
- HIV-specific CD8⁺ T cells and HIV eradication.The Journal of clinical investigation · 2016Review
- Programming T cell Killers for an HIV Cure: Teach the New Dogs New Tricks and Let the Sleeping Dogs Lie.Forum on immunopathological diseases and therapeutics · 2015Article
- Preserving HIV-specific T cell responses: does timing of antiretroviral therapy help?Current opinion in HIV and AIDS · 2015Review
- Article
- HIV-Specific CD8(+) T Lymphocytes in Blood of Long-Term HIV-Infected Hemophilia Patients.BioResearch open access · 2013Article
- Biologically-directed modeling reflects cytolytic clearance of SIV-infected cells in vivo in macaques.PloS one · 2012Article
- Professional antigen presenting cells in human herpesvirus 8 infection.Frontiers in immunology · 2012Article
- Dendritic cells reveal a broad range of MHC class I epitopes for HIV-1 in persons with suppressed viral load on antiretroviral therapy.PloS one · 2010Article
- Article
- Utilizing the FIV model to understand dendritic cell dysfunction and the potential role of dendritic cell immunization in HIV infection.Veterinary immunology and immunopathology · 2010Review
- Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection.Clinical and vaccine immunology : CVI · 2009Article
- Dendritic cell-based human immunodeficiency virus vaccine.Journal of internal medicine · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
The long-term efficacy of combination antiretroviral therapy may relate to augmentation of anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) T-cell responses. We found that prolonged treatment of late-stage HIV-1-infected patients with a protease inhibitor and two nucleoside reverse transcriptase inhibitors failed to restore sustained, high levels of HIV-1-specific, HLA class I-restricted, cytotoxic-T-lymphocyte precursors and gamma interferon (IFN-gamma) production by CD8(+) T cells. In some patients, particularly those initiating three-drug combination therapy simultaneously rather than sequentially, there were early, transient increases in the frequency of anti-HIV-1 CD8(+) T cells that correlated with decreases in HIV-1 RNA and increases in T-cell counts. In the other patients, HIV-1-specific T-cell functions either failed to increase or declined from baseline during triple-drug therapy, even though some of these patients showed suppression of plasma HIV-1 RNA. These effects of combination therapy were not unique to HIV-1 specific T-cell responses, since similar effects were noted for CD8(+) T cells specific for the cytomegalovirus pp65 matrix protein. The level and breadth of CD8(+) cell reactivity to HLA A*02 HIV-1 epitopes, as determined by IFN-gamma production and HLA tetramer staining after combination therapy, were related to the corresponding responses prior to treatment. There was, however, a stable, residual population of potentially immunocompetent HIV-1-specific T cells remaining after therapy, as shown by tetramer staining of CD8(+) CD45RO(+) cells. These results indicate that new strategies will be needed to target residual, immunocompetent HIV-1-specific CD8(+) T cells to enhance the effectiveness of antiretroviral therapy in patients with advanced immunodeficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.